Capital is shifting, and the moves are telling. Utilities and healthcare — the two sectors investors ignore during bull markets — are attracting institutional inflows as market breadth narrows and economic uncertainty rises. Here are five high-yield defensive picks worth a closer look.
The setup
Narrow market leadership has been the defining feature of 2026. The top 10 stocks in the S&P 500 account for over 35% of index weight. When breadth contracts this tightly, defensive sectors historically outperform in the subsequent rotation. Utilities and healthcare tend to attract capital first because they offer yield, stability, and pricing power regardless of the economic cycle.
Recent institutional data confirms the shift. Utilities ETF inflows hit $4.2 billion in the last four weeks. Healthcare fund inflows reached $3.8 billion over the same period. Both sectors are outperforming the S&P 500 on a trailing 30-day basis.
Key numbers
| Stock | Yield | YTD Return | P/E Ratio | 5Y Div CAGR | Payout Ratio |
|---|---|---|---|---|---|
| NextEra Energy (NEE) | 3.0% | +8.2% | 24x | 9.8% | 62% |
| Duke Energy (DUK) | 4.1% | +6.5% | 19x | 4.2% | 72% |
| Southern Company (SO) | 4.0% | +5.8% | 21x | 3.6% | 68% |
| Johnson & Johnson (JNJ) | 3.1% | +4.1% | 16x | 5.8% | 74% |
| AbbVie (ABBV) | 3.5% | +7.9% | 18x | 12.4% | 54% |
What to watch
NextEra Energy (NEE) benefits from two tailwinds: regulated utility earnings and data center power demand. The company’s Florida regulated utility provides stable base earnings, while its renewable energy segment positions it for the AI-driven electricity demand surge. At a 62% payout ratio, the 3.0% yield is well-covered with room for continued 10% dividend growth.
Duke Energy (DUK) operates in the Carolinas, Florida, and the Midwest — regions experiencing population growth and industrial expansion. Rate case approvals in late 2025 and early 2026 provide earnings visibility. The 4.1% yield is attractive for income investors, and the stock’s defensive characteristics shine in volatile markets.
Johnson & Johnson (JNJ) completed its medtech split and now trades as a pure pharmaceutical and medical device company. Pipeline assets in oncology and immunology compensate for Stelara biosimilar competition. The 62-year dividend growth streak is the second longest in the S&P 500.
AbbVie (ABBV) deserves a second mention here because it bridges healthcare and defensive income. Humira biosimilar revenue erosion is well-understood and largely priced in. Rinvoq and Skyrizi are scaling faster than expected. The 3.5% yield with a 54% payout ratio offers both income and dividend growth.
Bottom line
Defensive rotation does not mean hiding in cash. It means owning companies that generate reliable earnings and grow dividends through economic uncertainty. Utilities provide yield and data center demand. Healthcare offers demographic tailwinds and pricing power. For conservative investors, a mix of NEE, DUK, JNJ, and ABBV provides diversified income with growth optionality.
Stay ahead with our weekly newsletter
Receive sector rotation analysis, defensive stock screens, and income investing strategies every week. Subscribe to the free AlphaBetaStock newsletter — concise, data-driven, and free.
